Sarepta Therapeutics, Inc. SRPT Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| —— | $235.24M+140% | -$581.63M+17.3% | -$703.49M-68.0% | ||
| $44.52M+18.0% | $37.72M-15.0% | $44.4M+6.1% | $41.86M+10.1% | ||
| $123.4M-33.0% | $184.3M+1.0% | $182.51M-21.7% | $233.02M+105% | ||
| —— | —— | -$500.99M-54.0% | -$325.35M+26.6% | ||
| $101.97M-25.5% | $136.96M+80.0% | $76.11M+147% | $30.82M-19.9% | ||
| —— | —— | -$165.8M— | —— | ||
| —— | —— | —— | $0— | ||
| —— | —— | —— | $550M— | ||
| -$168.34M-235% | $124.81M-0.2% | $125M-46.2% | $232.51M-58.6% | ||
| —— | $674.58M+225% | -$541.79M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Sarepta Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.